Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $45.08M worth of Stoke Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $17.49M and sold $13.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.
2024-06-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $15.22 | $152,185 | -1.81% | |
2024-05-20 | Sale | Kaye Edward M. MD | CEO | 42,350 0.0779% | $15.43 | $653,529 | -7.01% | |
2024-05-20 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 8,599 0.0154% | $15.04 | $129,327 | -7.01% | |
2024-05-20 | Sale | Nash Huw M. | COO & CBO | 50,000 0.0917% | $15.39 | $769,500 | -7.01% | |
2024-05-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0189% | $11.37 | $113,653 | +24.55% | |
2024-04-17 | Sale | Skorpios Trust | 10 percent owner | 3.6M 6.8708% | $11.60 | $41.76M | +19.49% | |
2024-04-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 9,426 0.02% | $13.23 | $124,684 | -2.89% | |
2024-04-01 | Sale | Nash Huw M. | COO & CBO | 61,329 0.1299% | $13.23 | $811,212 | -2.89% | |
2024-03-28 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 5,126 0.0108% | $13.20 | $67,668 | -1.52% | |
2024-03-19 | Sale | Kaye Edward M. MD | CEO | 11,150 0.0263% | $6.10 | $67,999 | +125.30% | |
2024-03-19 | Sale | Tulipano Stephen J | CFO | 4,116 0.0097% | $6.10 | $25,102 | +125.30% | |
2024-03-19 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 4,116 0.0097% | $6.10 | $25,102 | +125.30% | |
2024-03-19 | Sale | Nash Huw M. | COO & CBO | 4,116 0.0097% | $6.10 | $25,102 | +125.30% | |
2024-03-19 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 2,349 0.0055% | $6.10 | $14,326 | +125.30% | |
2024-03-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.0231% | $7.75 | $77,469 | +64.10% | |
2024-02-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 10,000 0.022% | $4.80 | $47,991 | +142.54% | |
2024-01-02 | Sale | Ticho Barry | Chief Medical Officer | 10,000 0.0218% | $5.74 | $57,352 | +91.57% | |
2023-07-03 | Sale | Ticho Barry | Chief Medical Officer | 15,000 0.0351% | $10.60 | $158,973 | -47.94% | |
2023-06-21 | Sale | Allan Jonathan | General Counsel & Corp Sec | 1,948 0.0046% | $13.48 | $26,252 | -58.67% | |
2023-06-01 | Sale | Ticho Barry | Chief Medical Officer | 15,000 0.0348% | $11.13 | $166,964 | -50.62% |
Skorpios Trust | 10 percent owner | 10843681 20.9098% | $12.92 | 0 | 1 | |
Ticho Barry | CHIEF MEDICAL OFFICER | 2485 0.0156% | $12.92 | 0 | 21 | |
Tulipano Stephen J | CFO | 20746 0.0013% | $12.92 | 0 | 6 | |
Nash Huw M. | COO & CBO | 0 0% | $12.92 | 0 | 29 | |
Allan Jonathan | General Counsel & Corp Sec | 2598 0% | $12.92 | 0 | 4 | |
Kaye Edward M. MD | CEO | 27000 0% | $12.92 | 0 | 6 | |
Harrison Seth Loring | 17161713 38.4328% | $12.92 | 2 | 0 | <0.0001% | |
Apple Tree Partners IV, L.P. | 10 percent owner | 17161713 38.4328% | $12.92 | 2 | 0 | <0.0001% |
RTW INVESTMENTS, LP | 10 percent owner | 3544248 7.9372% | $12.92 | 6 | 1 | <0.0001% |
Liau Gene | EVP Research & Preclinical Dev | 21351 0.0478% | $12.92 | 0 | 7 | |
LEVIN ARTHUR A | director | 0 0% | $12.92 | 0 | 1 | |
Walker Robin A. | Chief Legal Officer, CCO & Sec | 0 0% | $12.92 | 0 | 1 | |
TZIANABOS ARTHUR | director | 0 0% | $12.92 | 0 | 2 |
Skorpios Trust | $194.99M | 27.71 | 14.44M | 0% | +$0 | 99.92 | |
Redmile Group | $68.49M | 9.73 | 5.07M | +93.22% | +$33.04M | 2.54 | |
RTW Investments, LP | $57.04M | 8.11 | 4.22M | +2.27% | +$1.27M | 0.84 | |
Morgan Stanley | $54.34M | 7.72 | 4.03M | +19.42% | +$8.84M | <0.01 | |
BlackRock | $52.09M | 7.4 | 3.86M | +87.28% | +$24.28M | <0.01 | |
Lynx1 Capital Management Lp | $49.91M | 7.09 | 3.7M | +25.02% | +$9.99M | 2.63 | |
Baker Bros Advisors LP | $45.47M | 6.46 | 3.37M | +65.92% | +$18.07M | 0.57 | |
Cowen Group | $45.44M | 6.46 | 3.37M | -9.56% | -$4.8M | 1.44 | |
The Vanguard Group | $23.16M | 3.29 | 1.72M | +4.07% | +$905,202.00 | <0.0001 | |
Goldman Sachs | $18.95M | 2.69 | 1.4M | +0.91% | +$170,424.00 | <0.01 | |
Franklin Templeton Investments | $14.29M | 2.03 | 1.06M | New | +$14.29M | <0.01 | |
Geode Capital Management | $8.64M | 1.23 | 639,807 | +3.91% | +$325,156.50 | <0.01 | |
State Street | $7.82M | 1.11 | 579,607 | +6.64% | +$486,999.03 | <0.0001 | |
Granahan Investment Management | $6.42M | 0.91 | 475,463 | -58.22% | -$8.94M | 0.23 | |
Cormorant Asset Management Lp | $5.77M | 0.82 | 427,163 | -60.73% | -$8.92M | 0.27 | |
Deutsche Bank | $5.57M | 0.79 | 412,240 | -0.13% | -$7,263.00 | <0.01 | |
Fidelity Investments | $5.07M | 0.72 | 375,481 | +7,409.62% | +$5M | <0.0001 | |
Artal Group S A | $4.05M | 0.58 | 300,000 | New | +$4.05M | 0.02 | |
Eversept Partners LP | $3.92M | 0.56 | 290,000 | New | +$3.92M | 0.3 | |
Healthcare Of Ontario Pension Plan Trust Fund | $3.56M | 0.51 | 263,700 | +10.2% | +$329,400.00 | 0.01 | |
Northern Trust | $3.52M | 0.5 | 260,891 | +1.28% | +$44,536.51 | <0.01 | |
Sio Capital Management LLC | $3.04M | 0.43 | 225,496 | New | +$3.04M | 1.08 | |
Charles Schwab | $3.01M | 0.43 | 223,038 | +8.67% | +$240,246.00 | <0.01 | |
Dimensional Fund Advisors | $2.97M | 0.42 | 219,765 | +2.08% | +$60,358.53 | <0.01 | |
Birchview Capital Lp | $2.83M | 0.4 | 210,000 | 0% | +$0 | 0.16 | |
D. E. Shaw & Co. | $2.62M | 0.37 | 193,760 | +35.77% | +$689,161.76 | <0.01 | |
Marshall Wace | $2.41M | 0.34 | 178,586 | New | +$2.41M | <0.01 | |
DAFNA Capital Management, LLC | $1.96M | 0.28 | 145,000 | New | +$1.96M | 0.46 | |
Wellington Management Company | $1.94M | 0.28 | 143,351 | New | +$1.94M | <0.0001 | |
Point72 Asset Management | $1.92M | 0.27 | 142,458 | New | +$1.92M | <0.01 | |
Palo Alto Investors Lp | $1.7M | 0.24 | 125,861 | New | +$1.7M | 0.19 | |
Nuveen | $1.62M | 0.23 | 119,811 | +89.18% | +$762,480.24 | <0.0001 | |
Woodline Partners LP | $1.44M | 0.21 | 106,904 | +87.87% | +$675,000.00 | 0.01 | |
Maven Securities Ltd | $1.35M | 0.19 | 100,000 | New | +$1.35M | 0.08 | |
Laurion Capital Management LP | $1.35M | 0.19 | 100,000 | New | +$1.35M | 0.04 | |
Gsa Capital Partners Llp | $1.32M | 0.19 | 97,508 | -4.5% | -$62,069.61 | 0.11 | |
Mirae Asset Global Investments Co Ltd | $728,024.00 | 0.17 | 90,663 | New | +$728,024.00 | <0.01 | |
BNY Mellon | $1.21M | 0.17 | 89,904 | -8.57% | -$113,724.09 | <0.0001 | |
Gilder Gagnon Howe & Co. LLC | $1.21M | 0.17 | 89,783 | +44.23% | +$371,722.65 | 0.02 | |
Susquehanna International Group | $1.07M | 0.15 | 79,526 | +273.64% | +$786,267.73 | <0.01 | |
Fort Point Capital Partners | $1.02M | 0.15 | 75,429 | 0% | +$0 | 0.14 | |
Monashee Investment Management LLC | $912,384.00 | 0.13 | 67,584 | New | +$912,384.00 | 0.08 | |
Los Angeles Capital Management LLC | $840,470.00 | 0.12 | 62,257 | 0% | +$0 | <0.01 | |
Squarepoint Ops LLC | $689,810.00 | 0.1 | 51,097 | +167.58% | +$432,013.81 | <0.01 | |
LMR PARTNERS LLP | $675,000.00 | 0.1 | 50,000 | New | +$675,000.00 | 0.02 | |
Jacobs Levy Equity Management | $646,812.00 | 0.09 | 47,912 | -71.49% | -$1.62M | <0.01 | |
State of Wisconsin Investment Board | $650,700.00 | 0.09 | 48,200 | -44.34% | -$518,400.00 | <0.01 | |
Eam Investors | $618,908.00 | 0.09 | 45,845 | New | +$618,908.00 | 0.1 | |
Millennium Management LLC | $620,784.00 | 0.09 | 45,984 | +92.29% | +$297,945.00 | <0.0001 | |
RhumbLine Advisers | $565,239.00 | 0.08 | 41,870 | +2.19% | +$12,136.37 | <0.01 |